eligibility_summary
Adults ≥18 with histologically/cytologically confirmed epithelial ovarian cancer that is platinum-resistant and measurable, ECOG 0–2, adequate organs (ANC≥1.5, PLT≥75, TBIL/AST/ALT≤2.5×ULN, Cr≤1.5×ULN), negative pregnancy test if applicable, life expectancy ≥12 wks, consent. Exclude: other cancer <1 yr, CNS mets/disorders, uncontrolled infection/cardiac/pulmonary/psychiatric disease, immunodeficiency/autoimmune, active HIV/HBV/HCV, pregnant/breastfeeding, noncompliance risk, other trial <4 wks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05776355 tests NKG2D CAR-NK cell therapy in platinum‑resistant recurrent epithelial ovarian cancer (single‑arm, dose‑escalation to define MTD). Intervention: Lymphodepleting chemotherapy followed by infusion of NKG2D CAR‑NK cells (gene‑modified cellular immunotherapy, biological). Mechanism: NK cells engineered with a chimeric receptor based on NKG2D to recognize stress‑induced ligands (MICA, MICB, ULBP family) on tumor cells, activating NK cytotoxic pathways and cytokine release to kill cancer cells, lymphodepletion enhances CAR‑NK expansion/persistence. Targets: NKG2D–ligand axis on ovarian tumor cells, innate NK effector pathways.